**Deadline 2021, October 31st**

***MATWIN*** *is a French open-innovation platform aiming at selecting and supporting preclinical or early clinical innovations in oncology to optimise their transfer potential for partners (pharma companies, biotechs, investors, etc.). The present form should describe your project from a translational point of view. To access our support, the project will first be reviewed by the MATWIN* [*International Board*](https://matwin.fr/en/matwin-international-board/)*. For assistance do not hesitate to ask your Technology Transfer Office and/or institutional partner (Canceropole, research institution…) or MATWIN.*

**Research Project**

|  |  |
| --- | --- |
| **Title** |  |
| **Acronym** |  |
| **Key words** |  |

**Project Coordinator**

|  |  |  |  |
| --- | --- | --- | --- |
| **Title; Name** |  | | |
| **Position** |  | | |
| **Lab / Organisation** |  | | |
| **Address** |  | | |
| **E-mail** |  | **Phone / Mobile** |  |

**For European project outside France – French established collaborator**

|  |  |  |  |
| --- | --- | --- | --- |
| **Collaboration type** |  | | |
| **Title; Name** |  | | |
| **Position** |  | | |
| **Lab / Organisation** |  | | |
| **Address** |  | | |
| **E-mail** |  | **Phone / Mobile** |  |

**Technology Transfer Office (*for academic team)* / Patent Office (*for start-up)***

|  |  |  |  |
| --- | --- | --- | --- |
| **Name** |  | | |
| **Contact name** |  | | |
| **Address** |  | | |
| **E-mail** |  | **Phone / Mobile** |  |

1. **ABSTRACT (400 words MAX - NOT CONFIDENTIAL)**

(Summarize your project as NOT confidential, to allow diffusion to peers without jeopardizing proprietary information). **Only the abstract must be considered as NOT confidential.**

👉 Please, note that your summary must answers the followings and indicate your French established collaboration *(for NON French European applicants only)*:

1. Application domain

2. Innovative component / Competitive differentiator

3. Objectives

4. Concept

5. Methodology

6. Expected results

7. Impact

1. **INTELLECTUAL PROPERTY**

**Patent 🡪 one table for each patent, filed or granted**

|  |  |
| --- | --- |
| Patent title |  |
| Date of patent filing |  |
| Patent co-owners (institutions) |  |
| National / PCT / WO number |  |
| Freedom To Operate ? Y/N - Patent officer (1 page summary to be joined) |  |
| Potential agreement (license) limiting use of IP? Involved parties & type of agreement? |  |

1. **SCIENTIFIC PROJECT (4-5 PAGES MAX - CONFIDENTIAL)**

* **Context and background (A HALF PAGE MAX):** Describe succinctly the context and the goal to be reached **including the 4-5 more relevant publication references.**
* **Current stage of development (3-4 PAGES MAX):** Describe the project’s development stage relative to the goal to be reached **(bullet points)**, including **the essential / relevant datas** justifying your claims regarding the mechanism of action, the proof of concept, benchmarking, etc. with **3-4 figures** of the most relevant and differentiating data.
* **Research & development plan (A HALF PAGE MAX):** List (bullet points) the main steps and GO/No GO to achieve the final goal

# UNDERTAKING

## Project Leader (and TTO representative if applicable)

*The parties, undersigned confirm that they (i) completed all sections and that all information given in this form is complete and true, (ii) obtained the agreement of collaborators and institutional contacts for their participation (iii)* ***fully agree with the Charter on Rights and Duties of MATWIN applicants (see attached Appendix)****. The parties authorise MATWIN to share this application form for assessment, given that each person who accesses this document is engaged through a confidentiality agreement with MATWIN (as described in the attached MATWIN Charter).*

|  |  |
| --- | --- |
| **Name of the leader applicant :** | **Name of the TTO legal representative :** |
| **Date and Signature** | **Date and Signature** |

File to be sent to: [emmanuel.conseiller@matwin.fr](mailto:emmanuel.conseiller@matwin.fr) before October 31st, 2021

**APPENDIX – IMPORTANT (to be read before applying)**

**MATWIN Charter**

**Rights and Duties**

MATWIN, a fully owned subsidiary of UNICANCER group, is the private company supporting the MATWIN programme which relies on a collaborative process with major pharmaceutical and diagnostic companies and a team of international scientific experts. The main objective of the programme is to support and accelerate the development of early stage innovation in oncology with high transfer potential and to foster collaboration opportunities with partners (pharma companies, biotechs, investors).

MATWIN, acting like a mutualized projects sourcing platform for industrial partners, is fully committed to increase the international attractiveness of research in oncology and to identify and qualify the projects in order to connect them with the most appropriate/suitable partners.

MATWIN’s operational decisions rely on an International multidisciplinary Board which meets annually (referred to hereinafter as “MATWIN Board”) gathering key opinion leaders in oncology from all Europe and industrial representatives from the MATWIN industrial partners. This committee is in charge of assessing the submitted projects and after each annual Board meeting, every industrial partner has a prior right to express an interest on developing (or co-developing) projects.

When applying to MATWIN, the candidates (and their Technology Transfer Office when applicable) fully agree with the following Rights and Duties of MATWIN and applicants. They also agree, if eligible to the MATWIN support, to sign an agreement with MATWIN addressing the different items below.

**MATWIN’s duties**

1. **Best practices**

The MATWIN Programme has been implemented according to the best practices in order to meet the requirements of technology transfer at the preclinical/early clinical stage.

MATWIN undertakes to make every effort with the support of the major research and care institutions, to:

* + Identify the best projects in oncology from the whole European territory;
  + Help to structure these projects in accordance with the industrial partners’ requirements;
  + Shorten the development period in order to boost availability of possible therapeutic innovations.

1. **Applicants visibility**

MATWIN undertakes to give the best visibility to every submitted project in order to reinforce sourcing opportunities.

MATWIN undertakes to raise greater awareness of every submitted project by providing access to the industrial partners represented at the highest level on the MATWIN Board (International Global executive, Early development, drug discovery or oncology position) of all the necessary documents to ease its assessment.

MATWIN undertakes to provide all necessary efforts to facilitate intermediation between submitted projects after their presentation to the MATWIN Board by requesting from the industrial Board members and partners (the 'Partners') to indicate a potential prior interest on projects presented to the MATWIN Board.

In case of an interest on one or several projects, MATWIN Partners may mandate the platform to provide a support on coordinating and following the exchanges with the applicants and IP owners (and/or their legal representatives) until the signature of a potential partnership or transfer agreement regarding the concerned project(s). On top of these, MATWIN undertakes to provide all necessary efforts all along the programme and after to facilitate intermediation with any relevant partner for the project (Technology Transfer Offices, Biotech companies, Investors …).

1. **Confidentiality**

MATWIN undertakes ensuring confidentiality related to every submitted project by prohibiting internal and external communication of any confidential document without the applicant's prior written approval.

Generally speaking, each stakeholder of the MATWIN programme (MATWIN employees, experts, coaches, members and invited members of the MATWIN Board) undertakes not to publish or disclose under no circumstances the confidential scientific or technical information and datas belonging to the applicants by signing a confidential agreement with MATWIN prior having access to any of these information.

**The Applicant’s duties**

1. **Best practices and divulgation**

The applicant guarantees the accuracy of scientific data presented all along the MATWIN Programme as well as their origin.

According to MATWIN's confidentiality duties, the applicant undertakes providing all scientific information and datas all along the MATWIN process for an optimal assessment of the project. In case the applicant may refuse to share the expected scientific information and datas, he takes the risk of being excluded from the MATWIN Programme.

1. **Transparency / Information**

The applicant undertakes keeping MATWIN informed of any discussion and any agreement that may be initiated or signed as a (direct or indirect) consequence of the MATWIN Programme.

This encompasses:

* Maturation or extension of a maturation programme agreed with a Technology Transfer Office
* Start-up creation
* Collaboration agreement, licensing agreement
* Funding agreement, fundraising, crowdfunding, etc.

The applicant undertakes facilitating the use by MATWIN of such information for advertising on and promoting the MATWIN Programme.

1. **Financial duties**
   1. **Reimbursement of MATWIN Programme costs**

**The French applicants** undertake to reimburse the overall cost of the MATWIN support Programme they benefited from in case of any funding agreement that may be concluded post MATWIN process being a direct or indirect consequence of it.

This encompasses:

* Any agreement generating extra revenues for the project (licensing agreement -even optional- or transfer agreement)
* Funding agreement, fundraising, crowdfunding, etc.

A direct consequence is defined as a MATWIN partner positioning who is:

* An already established partner of the MATWIN programme
* A partner proposed by MATWIN with whom the applicant was not already in touch with (or if in touch, with a different representative)

An indirect consequence is defined as:

* A partner involved in the MATWIN process, that can facilitate intermediation with any external structure
* A partner that has been sensitized thanks to the MATWIN label

**The non-French European applicants** having access to a specific support, thus undertake to reimburse the costs of the MATWIN Programme they benefited from, according to final step reached within the MATWIN process, and regardless of the outcome of the project in the MATWIN process (successful or not).

The costs associated to the MATWIN support Programme are listed below:

* Step 1 = Written Board feedback post 1st pitch of preselection (alone): 2.000 €
* Step 2 = Coaching - 2 sessions : Development plan review + Training before Board meeting (alone): 4.000 €
* Step 3 = Board presentation + written feedback from each Board member & final MATWIN synthesis (not accessible alone)


|  |  |
| --- | --- |
| **MATWIN usual support process (6 months)** | **MATWIN accelerated support process (3 months)** |
| Having access to Step 1 + 2 + 3  If selected for the final Board meeting presentation, the total cost of the MATWIN usual support is **10.000 € V.A.T** **excl.** | Having access to half of Step 2 + Step 3  If selected for the final Board meeting presentation, the total cost of the MATWIN accelerated support is **5.000 € V.A.T** **excl.** |

* 1. **Fees for success**

In case of any success as described previously (§ 3.1) that may be concluded as a direct consequence of the MATWIN Programme, generating a first phase of funding for the preclinical or clinical development of the project, the applicant (and its Technology Transfer Office when applicable) undertakes to pay success fees to MATWIN.

These success fees due to MATWIN from the applicant (or its Technology Transfer Office when applicable) will be calculated on the basis of 7% of generated funding during the preclinical or clinical development period (but limited to 30k€ max). In that context, the applicant agrees to sign with MATWIN an agreement addressing the success fees.

The MATWIN Programme costs that would have already been paid, will be deducted from the success fees.



Pierre FUMOLEAU

MATWIN President

